Atlas Trials

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Clinical trial NCT06256484 · TERMINATED

Trial details

NCT number
NCT06256484
Sponsor
Atara Biotherapeutics
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Start date
2024-09-06
Primary completion
2025-03-03
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.